ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Glaxo Cuts R&D Jobs, Eyes Restructuring

June 16, 2008 | APPEARED IN VOLUME 86, ISSUE 24

GlaxoSmithKline is looking to shake up its approach to R&D. Patrick Vallance, head of drug discovery, told the BioIndustry Association's Biofinance & Bioinnovate Europe 2008 conference in London last week that GSK wants to split up its research programs into even smaller, focused groups to become "more biotech-like." Several years ago, GSK restructured its research organization into eight autonomous groups it calls centers of excellence for drug discovery. Any new change in GSK's research structure would come as the company is cutting R&D jobs. Last week, major job cuts were announced at GSK's R&D sites in Research Triangle Park, N.C.; Upper Providence, Pa.; Upper Merion, Pa.; Harlow, England; and Verona, Italy. In total, the company plans to shed some 2% of its 17,000 global R&D workforce.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment